Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
Janus kinase (JAK) and signal transducer and activator of transcription (STAT) signalling has been established to have pathophysiological role in multiple disease states, such as myeloproliferative neoplasms, rheumatoid arthritis, inflammatory bowel disease and multiple immune-driven dermatological...
Saved in:
Main Authors: | Vishal R. Tandon (Author), Annil Mahajan (Author) |
---|---|
Format: | Book |
Published: |
Dr. Annil Mahajan,
2022-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effectiveness of Janus kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis
by: A. E. Cheberda, et al.
Published: (2024) -
Epigenetic targets of Janus kinase inhibitors are linked to genetic risks of rheumatoid arthritis
by: Haruka Tsuchiya, et al.
Published: (2024) -
Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders
by: Robert Roskoski, Jr
Published: (2022) -
More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review's Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
by: Paul Langley
Published: (2020) -
Systematic review of Janus kinases inhibitors for rheumatoid arthritis: methodology, reporting, and quality of evidence evaluation
by: Xiaolan Shen, et al.
Published: (2024)